Get startedLog in
    Picture of Takeda Pharmaceutical logo

    TAK — Takeda Pharmaceutical News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareConservativeLarge CapHigh Flyer
    All News

    Brief: U.S. FDA Accepts Takeda's Application For Intravenous Entyvio® (Vedolizumab) In Pediatric Ulcerative Colitis And Crohn's Disease

    Picture of Takeda Pharmaceutical logoTakeda Pharmaceutical
    09/06/2026 21:40
    BRIEF-U.S. FDA Accepts Takeda's Application For Intravenous Entyvio® (Vedolizumab) In Pediatric Ulcerative Colitis And Crohn's Disease
    June 9 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T:
    • U.S. FDA ACCEPTS TAKEDA'S APPLICATION FOR INTRAVENOUS ENTYVIO® (VEDOLIZUMAB) IN PEDIATRIC ULCERATIVE COLITIS AND CROHN'S DISEASE
    • TAKEDA PHARMACEUTICAL CO - FDA SETS PDUFA GOAL DATE IN Q1 2027 FOR ENTYVIO APPLICATION
    Source text: ID:nBwb9nn9a
    Further company coverage: 4502.T

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Takeda Pharmaceutical

    See all news